Clinical Trial Update: A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) [Phase 3]

View source ↗

Summary

A Phase 3 trial (KEYNOTE-048) evaluated pembrolizumab as first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma. The results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer | Phase 3 | Status: COMPLETED | Results posted: 2020-02-17